<DOC>
	<DOCNO>NCT02407327</DOCNO>
	<brief_summary>The purpose study determine percentage CTC-positive patient total CTC number patient advance Non Small Cell Lung Cancer .</brief_summary>
	<brief_title>Individualized Treatment Patients With Advanced NSCLC : Potential Application Circulating Tumor Cells ( CTC ) Molecular Phenotypical Profiling</brief_title>
	<detailed_description>The primary aim Project determine percentage CTC-positive patient total CTC number advance NSCLC baseline , start treatment . To valuate CTC count modification early predictor response treatment prospective observational study conduct , consecutively enrol 150 patient regardless type line therapy , reevaluate disease status CTC count depend type schedule treatment . Furthermore , purify CTC obtain automate platform DNA sequence perform assess sensitize mutation advance NSCLC patient . The EGFR mutation EML4-ALK fusion gene detect CTC compare report tumor specimen use standard sequencing . In parallel , CTC count assay integrated mAb target EGFR EML4-ALK fusion gene , test whether assay quote EGFR-positive ALK-positive CTC provide sensitive marker rating pharmacodynamic effect patient compare total CTC count . Moreover , report NSCLC cell EGFR mutation manifest activation PI3K ( phosphatidylinositol 3-kinase ) -AKT MEK-ERK ( extracellular signal-regulated kinase ) signal pathway control EGFR , exposure cell EGFR-TKIs block signal pathway induces apoptosis 13 . To evaluate whether live vs. apoptotic CTC change treatment may use predictor tumor response , M30-positive CTC quantify previously 8 . Data obtain CTC assay correlate common prognostic factor .</detailed_description>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Neoplastic Cells , Circulating</mesh_term>
	<criteria>Age 1880 year old , males female ; Patients NSCLC confirm histopathology cytology ; Life expectancy &gt; 6 month ; Patients voluntary participate sign informed content Any condition might hamper compliance schedule assessment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Circulating tumour cell Advanced Non Small Cell Lung Cancer</keyword>
</DOC>